In this study, we encapsulated the commercial drug (DXTL), into PLGA NPs by using the single emulsion-evaporation method. This study reports physical and chemical properties of the DXTL-PLGA NPs. The DXTL-PLGA NPs displayed a particle size of 180 nm, as determined by scanning electron microscopy (SEM). The entrapment and loading efficiency of DXTL-PLGA NPs were 96.4% and 10.1%, respectively. Zeta potential and electrophoretic mobility experiments revealed that DXTL-PLGA NPs have a negative charge of -39.6 ± 0.6 mV and a mobility of -3.1 µmcm/Vs, suggesting that PLGA NPs encapsulating DXTL form stable dispersion in water. In adittion, DXTL NPs will be assesed by using the highly metastatic prostic cancer cell line PC3. The main outcome of this study is that by encapsulating compound DXTL into PLGA NPs will result in an enhancement of its anticancer activity against PC3 when compared to free DXTL.

Preparation of docetaxel (Dxtl)-encapsulated poly (lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) and their potential as anticancer agent against highly metastatic prostate cancer cells

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.